Galectin Therapeutics (GALT) Free Cash Flow (2010 - 2026)

Galectin Therapeutics' Free Cash Flow history runs 17 years deep, the most recent figure standing at -$3.9 million for Q1 2026.

• In Q1 2026, Free Cash Flow rose 49.79% year-over-year to -$3.9 million; the TTM figure through Mar 2026 stood at -$20.1 million (up 46.3% YoY), while the FY2025 annual figure was -$23.9 million, up 42.78% from the prior year.
• Free Cash Flow was -$3.9 million for Q1 2026 at Galectin Therapeutics, up from -$6.1 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of -$3.5 million in Q3 2025 to a low of -$12.8 million in Q4 2024.
• Historically, Free Cash Flow has averaged -$7.9 million across 5 years, with a median of -$7.7 million in 2025.
• The sharpest annual moves came in 2024 and 2025: Free Cash Flow sank 170.02% in 2024, then jumped 59.19% in 2025.
• A 5-year view of Free Cash Flow shows it stood at -$7.2 million in 2022, then surged by 34.56% to -$4.7 million in 2023, then tumbled by 170.02% to -$12.8 million in 2024, then surged by 52.31% to -$6.1 million in 2025, then soared by 36.62% to -$3.9 million in 2026.
• The last three Free Cash Flow figures came in at -$3.9 million (Q1 2026), -$6.1 million (Q4 2025), and -$3.5 million (Q3 2025), per Business Quant data.